AzaSite

ApprovedSmall molecule

Merck & Co.

AzaSite is one of 61 small molecule programs targeting Bacterial Conjunctivitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial ConjunctivitisActive, not recruiting

BlepharitisActive, not recruiting

CataractActive, not recruiting

Bacterial ConjunctivitisPhase 3

Active, not recruiting

BlepharitisPhase 3

Active, not recruiting

CataractApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Phase 3

1 2

AzaSite

Merck & Co.

Approved

1 3

Intranasal Dexmedetomidine

BBaudax Bio

Phase 3

1 4

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 5

Mapracorat

Bayer

Phase 3

4 6

ISV-305

Sun Pharmaceutical Industries Limited

Phase 3

2 7

Idose TR

GGlaukos Corporation

Phase 3

1 8

Zolymbus

AbbVie

Preclinical

—9

Neurontin

VViatris Specialty LLC

Preclinical

3 10

Kenalog

BBassett Healthcare

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blepharitis6 trials

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00629941·25 enrolled

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00629590·20 enrolled

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00629980·60 enrolled

Show 3 more trials

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Completed·AAlcon Research·Phase 3·NCT01102244·122 enrolled

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

Completed· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 3·NCT01408082·917 enrolled

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00656539·20 enrolled

Bacterial Conjunctivitis2 trials

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00105469·743 enrolled

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00105534·685 enrolled

Cataract1 trial

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00575380·116 enrolled

Unspecified2 trials

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00575367·37 enrolled

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

Withdrawn·PPhiladelphia Eye Associates·Phase 2·NCT01797107

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for AzaSite. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AzaSite compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AzaSite. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

AzaSite

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blepharitis6 trials

Bacterial Conjunctivitis2 trials

Cataract1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News